In:
Blood, American Society of Hematology, Vol. 128, No. 6 ( 2016-08-11), p. 774-782
Abstract:
Dasatinib, combined with low-intensity chemotherapy, gave 36% 5-year overall survival in Ph+ ALL patients older than age 55 years. Prospective monitoring of mutations may be useful to personalize therapy in Ph+ ALL patients not eligible for intensive therapies.
Type of Medium:
Online Resource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood-2016-02-700153
Language:
English
Publisher:
American Society of Hematology
Publication Date:
2016
detail.hit.zdb_id:
1468538-3
detail.hit.zdb_id:
80069-7